Adma Biologics (ADMA) Net Margin (2011 - 2025)

Adma Biologics has reported Net Margin for 13 years, with the latest figure at 35.48% in Q4 2025.

• For the quarter ending Q4 2025, Net Margin fell 5971.0% year-over-year to 35.48%; the trailing twelve-month figure through Dec 2025 stood at 28.8% (down 1755.0% YoY), and the FY2025 full-year result was 28.8%, down 1755.0% from the prior year.
• Net Margin for Q4 2025 stood at 35.48%, up from 27.14% in the prior quarter.
• The five-year high for Net Margin was 95.19% in Q4 2024, with the low at 114.26% in Q1 2021.
• Historically, Net Margin has averaged 9.56% across 5 years, with a median of 4.13% in 2023.
• Annual changes were most pronounced in 2021 — Net Margin surged 11552 bps — and 2025, when it slumped 5971 bps.
• Adma Biologics' Net Margin stood at 30.01% in 2021, then increased by 21 bps to 23.59% in 2022, then soared by 161 bps to 14.33% in 2023, then jumped by 564 bps to 95.19% in 2024, then tumbled by 63 bps to 35.48% in 2025.
• The last three Net Margin figures came in at 35.48% (Q4 2025), 27.14% (Q3 2025), and 28.05% (Q2 2025), per Business Quant data.